Cancer News and Research

Latest Cancer News and Research

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.

19 Mar 2010

Survey unveils impact of gene regulation on human health

Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.

19 Mar 2010

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE™ technology for delivery of genes into cells.

18 Mar 2010

Solos Endoscopy secures U.S. Trademark for MammoView name

Solos Endoscopy, Inc. is pleased to announce the Company has secured the U.S. Trademark for the MammoView® name. The MamoView® Breast Endoscopy System offers a state-of-the-art endoscopic technology for detecting early stage breast cancer. The Company's Breast Endoscopy System employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of breast cancers arise.

18 Mar 2010

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.

18 Mar 2010

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.

18 Mar 2010

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Manitobans with wet age-related macular degeneration (AMD) received a dose of good news. The Manitoba government announced that Lucentis (ranibizumab injection) will soon be funded through a centralized vision program, effective June 1, 2010.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Risk of hereditary form of bowel cancer: New preparation of omega-3 holds hope

A new preparation of an omega-3 polyunsaturated fatty acid found naturally in fish, offers hope for thousands of patients at risk of developing an inherited form of bowel cancer, a new study shows.

18 Mar 2010

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.

18 Mar 2010

Canadian Cancer Society launches daffodil pin campaign to fight back against cancer

The Canadian Cancer Society, BC and Yukon, is stepping up the fight by announcing today the launch of an inaugural daffodil pin - a badge of courage - as part of its annual Daffodil month campaign when canvassers go door-to-door.

18 Mar 2010

Concord Medical Services Holdings reports 24.3% increase in total net revenues for fourth-quarter 2009

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the fourth quarter and fiscal year ended December 31, 2009(1), and the appointment of Dr. Hongbin Cai as an independent board member.

18 Mar 2010

Researchers find some similarities between SPN and PET

Solid-pseudopapillary neoplasm (SPN) of the pancreas is relatively rare. There are some similarities between SPN and pancreatic endocrine tumor (PET), especially the non-functioning ones, in clinical and pathological manifestations.

18 Mar 2010

Therapeutic may not be effective on trauma patients with undiagnosed Helicobacter infections

A Kansas State University study aimed at alleviating intestinal damage in trauma patients digressed to an important finding that could affect medication given to the individuals.

18 Mar 2010

Study finds the cost of cancer care is skyrocketing

USA Today: "The cost of cancer treatment is 'skyrocketing' — both for individual patients and the nation, a new analysis shows. From 1990 to 2008, spending on cancer care soared to more than $90 billion from $27 billion. The increase was driven by the rising costs of sophisticated new drugs, robotic surgeries and radiation techniques, as well as the growing number of patients who are eligible to take them, says Peter Bach of New York's Memorial Sloan-Kettering Cancer Cancer, co-author of an analysis in today's Journal of the American Medical Association.

18 Mar 2010

New book exposes the ignored causes of three major life-threatening and chronic diseases

In his newest book, "Overlooked Causes and the Prevention: Cancer, Cardiovascular Heart Disease, Multiple Sclerosis" (published by AuthorHouse), author Arthur Douglass Alexander III exposes, delineates and documents the sometimes overlooked and often ignored causes of three major life-threatening and chronic diseases: cancer, cardiovascular disease and multiple sclerosis.

18 Mar 2010

AVEO Pharmaceuticals completes initial public offering of 9M common stock shares at $9.00 per share

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per share, resulting in aggregate net proceeds to AVEO of approximately $72,580,000 after deducting underwriting discounts and commissions and estimated offering expenses.

18 Mar 2010

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Survey unveils impact of gene regulation on human health

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Solos Endoscopy secures U.S. Trademark for MammoView name

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Risk of hereditary form of bowel cancer: New preparation of omega-3 holds hope

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

Canadian Cancer Society launches daffodil pin campaign to fight back against cancer

Concord Medical Services Holdings reports 24.3% increase in total net revenues for fourth-quarter 2009

Researchers find some similarities between SPN and PET

Therapeutic may not be effective on trauma patients with undiagnosed Helicobacter infections

Study finds the cost of cancer care is skyrocketing

New book exposes the ignored causes of three major life-threatening and chronic diseases

AVEO Pharmaceuticals completes initial public offering of 9M common stock shares at $9.00 per share

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in